(Q547551)

For the development of molecularly-targeted treatments for chronic myeloid leukemia, converting a fatal cancer into a manageable chronic condition. (English)

1 reference

reference URL

https://laskerfoundation.org/winners/molecularly-targeted-treatments-for-chronic-myeloid-leukemia/

Charles F. Kettering Prize

point in time

2002

1 reference

reference URL

http://www.gm.com/company/gmability/philanthropy/cancer_research/prize.htm

archive URL

https://web.archive.org/web/20070313231403/http://www.gm.com/company/gmability/philanthropy/cancer_research/prize.htm

title

GM Cancer Previous Prize Winners (English)

archive date

13 March 2007

retrieved

12 August 2012

Fellow of the Royal Society

point in time

2013

announcement date

2 May 2013

2 references

stated in

Who's Who

reference URL

https://web.archive.org/web/20140425000218/https://royalsociety.org/about-us/fellowship/new-fellows-2013/

retrieved

30 April 2022

Warren Alpert Foundation Prize

point in time

2000

award rationale

For development of Abl kinase inhibitors for use in the treatment of chronic myelogenous leukemia. (English)

1 reference

reference URL

https://warrenalpert.org/prize-recipients/nicholas-lydon

Clarivate Citation Laureates

2011

"for their development of imatinib and dasatinib, revolutionary, targeted treatments for chronic myeloid leukemia." (English)

1 reference

reference URL

https://clarivate.com/citation-laureates

retrieved

23 September 2023

Identifiers

Fellow of the Royal Society ID

0 references

1 reference

28 October 2013

0 references

0 references

0 references

(Q547551)

Nicholas Lydon

Statements

Identifiers

Sitelinks

Wikipedia(4 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)